Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy
Identifieur interne : 001C94 ( Main/Exploration ); précédent : 001C93; suivant : 001C95Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy
Auteurs : Johannes C. Stoof [Pays-Bas] ; Ania Winogrodzka [Pays-Bas] ; Freek L. Van Muiswinkel [Pays-Bas] ; Erik Ch Wolters [Pays-Bas] ; Pieter Voorn [Pays-Bas] ; Henk J. Groenewegen [Pays-Bas] ; J. Booij [Pays-Bas] ; Benjamin Drukarch [Pays-Bas]Source :
- European Journal of Pharmacology [ 0014-2999 ] ; 1999.
Abstract
Patients suffering from Parkinson's disease display severe and progressive deficits in motor behavior, predominantly as a consequence of the degeneration of dopaminergic neurons, located in the mesencephalon and projecting to striatal regions. The cause of Parkinson's disease is still an enigma. Consequently, the pharmacotherapy of Parkinson's disease consists of symptomatic treatment, with in particular l-dihydroxyphenylalanine (l-DOPA) and/or dopamine receptor agonists. These induce a dramatic initial improvement. However, serious problems gradually develop during long-term treatment. Therefore, a more rational, c.q. causal treatment is needed which requires the introduction of compounds ameliorating the disease process itself. The development of such compounds necessitates (1) more information on the etiopathogenesis, i.e., the cascade of events that ultimately leads to degeneration of the dopaminergic neurons, and (2) brain imaging methods, to estimate the extent of the degeneration of the dopaminergic neurons in the living patient. This is not only important for the early diagnosis, but will also allow to monitor the effectiveness of alleged neuroprotective compounds on a longitudinal base. In this paper, etiopathogenic mechanisms are highlighted along the line of the oxidative stress hypothesis and within this framework, attention is mainly focused on the putative role of glutathione, dopamine auto-oxidation and phase II biotransformation enzymes. Especially, drugs able to increase the activity of phase II biotransformation enzymes seem to elicit a broad-spectrum (neuro)protective response and look very promising leads for the development of neuroprotective treatment strategies in Parkinson's disease. New developments in brain imaging methods (single photon emission computed tomography (SPECT) and positron emission tomography (PET)) to visualize the integrity of the striatal dopaminergic neurons in humans are highlighted as well. Especially, the introduction of radioligands that bind selectively to the dopamine transporter seems to be a significant step forward for the early diagnosis of Parkinson's disease. Performing these brain imaging studies with fixed time intervals does not only create the possibility to follow the degeneration rate of the dopaminergic neurons in Parkinson's disease but also provides the opportunity to estimate therapeutic effects of putative neuroprotective agents in the individual patient.
Url:
DOI: 10.1016/S0014-2999(99)00260-5
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy</title><author><name sortKey="Stoof, Johannes C" sort="Stoof, Johannes C" uniqKey="Stoof J" first="Johannes C" last="Stoof">Johannes C. Stoof</name></author><author><name sortKey="Winogrodzka, Ania" sort="Winogrodzka, Ania" uniqKey="Winogrodzka A" first="Ania" last="Winogrodzka">Ania Winogrodzka</name></author><author><name sortKey="Van Muiswinkel, Freek L" sort="Van Muiswinkel, Freek L" uniqKey="Van Muiswinkel F" first="Freek L" last="Van Muiswinkel">Freek L. Van Muiswinkel</name></author><author><name sortKey="Wolters, Erik Ch" sort="Wolters, Erik Ch" uniqKey="Wolters E" first="Erik Ch" last="Wolters">Erik Ch Wolters</name></author><author><name sortKey="Voorn, Pieter" sort="Voorn, Pieter" uniqKey="Voorn P" first="Pieter" last="Voorn">Pieter Voorn</name></author><author><name sortKey="Groenewegen, Henk J" sort="Groenewegen, Henk J" uniqKey="Groenewegen H" first="Henk J" last="Groenewegen">Henk J. Groenewegen</name></author><author><name sortKey="Booij, J" sort="Booij, J" uniqKey="Booij J" first="J" last="Booij">J. Booij</name></author><author><name sortKey="Drukarch, Benjamin" sort="Drukarch, Benjamin" uniqKey="Drukarch B" first="Benjamin" last="Drukarch">Benjamin Drukarch</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4503C2812219952F69B54AD379C2EC391439570C</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1016/S0014-2999(99)00260-5</idno><idno type="url">https://api.istex.fr/document/4503C2812219952F69B54AD379C2EC391439570C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002D77</idno><idno type="wicri:Area/Main/Curation">002999</idno><idno type="wicri:Area/Main/Exploration">001C94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy</title><author><name sortKey="Stoof, Johannes C" sort="Stoof, Johannes C" uniqKey="Stoof J" first="Johannes C" last="Stoof">Johannes C. Stoof</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Pays-Bas</country></affiliation></author><author><name sortKey="Winogrodzka, Ania" sort="Winogrodzka, Ania" uniqKey="Winogrodzka A" first="Ania" last="Winogrodzka">Ania Winogrodzka</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Van Muiswinkel, Freek L" sort="Van Muiswinkel, Freek L" uniqKey="Van Muiswinkel F" first="Freek L" last="Van Muiswinkel">Freek L. Van Muiswinkel</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Psychiatry, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Wolters, Erik Ch" sort="Wolters, Erik Ch" uniqKey="Wolters E" first="Erik Ch" last="Wolters">Erik Ch Wolters</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Voorn, Pieter" sort="Voorn, Pieter" uniqKey="Voorn P" first="Pieter" last="Voorn">Pieter Voorn</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Anatomy, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Groenewegen, Henk J" sort="Groenewegen, Henk J" uniqKey="Groenewegen H" first="Henk J" last="Groenewegen">Henk J. Groenewegen</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Anatomy, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Booij, J" sort="Booij, J" uniqKey="Booij J" first="J" last="Booij">J. Booij</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, AMC, Meibergdreef 9, 1105 AZ, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Drukarch, Benjamin" sort="Drukarch, Benjamin" uniqKey="Drukarch B" first="Benjamin" last="Drukarch">Benjamin Drukarch</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Research Institute for Neurosciences, Vrije Universiteit, van der Boechorststraat 7, 1081 BT, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Pharmacology</title><title level="j" type="abbrev">EJP</title><idno type="ISSN">0014-2999</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1999">1999</date><biblScope unit="volume">375</biblScope><biblScope unit="issue">1–3</biblScope><biblScope unit="page" from="75">75</biblScope><biblScope unit="page" to="86">86</biblScope></imprint><idno type="ISSN">0014-2999</idno></series><idno type="istex">4503C2812219952F69B54AD379C2EC391439570C</idno><idno type="DOI">10.1016/S0014-2999(99)00260-5</idno><idno type="PII">S0014-2999(99)00260-5</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2999</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients suffering from Parkinson's disease display severe and progressive deficits in motor behavior, predominantly as a consequence of the degeneration of dopaminergic neurons, located in the mesencephalon and projecting to striatal regions. The cause of Parkinson's disease is still an enigma. Consequently, the pharmacotherapy of Parkinson's disease consists of symptomatic treatment, with in particular l-dihydroxyphenylalanine (l-DOPA) and/or dopamine receptor agonists. These induce a dramatic initial improvement. However, serious problems gradually develop during long-term treatment. Therefore, a more rational, c.q. causal treatment is needed which requires the introduction of compounds ameliorating the disease process itself. The development of such compounds necessitates (1) more information on the etiopathogenesis, i.e., the cascade of events that ultimately leads to degeneration of the dopaminergic neurons, and (2) brain imaging methods, to estimate the extent of the degeneration of the dopaminergic neurons in the living patient. This is not only important for the early diagnosis, but will also allow to monitor the effectiveness of alleged neuroprotective compounds on a longitudinal base. In this paper, etiopathogenic mechanisms are highlighted along the line of the oxidative stress hypothesis and within this framework, attention is mainly focused on the putative role of glutathione, dopamine auto-oxidation and phase II biotransformation enzymes. Especially, drugs able to increase the activity of phase II biotransformation enzymes seem to elicit a broad-spectrum (neuro)protective response and look very promising leads for the development of neuroprotective treatment strategies in Parkinson's disease. New developments in brain imaging methods (single photon emission computed tomography (SPECT) and positron emission tomography (PET)) to visualize the integrity of the striatal dopaminergic neurons in humans are highlighted as well. Especially, the introduction of radioligands that bind selectively to the dopamine transporter seems to be a significant step forward for the early diagnosis of Parkinson's disease. Performing these brain imaging studies with fixed time intervals does not only create the possibility to follow the degeneration rate of the dopaminergic neurons in Parkinson's disease but also provides the opportunity to estimate therapeutic effects of putative neuroprotective agents in the individual patient.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Stoof, Johannes C" sort="Stoof, Johannes C" uniqKey="Stoof J" first="Johannes C" last="Stoof">Johannes C. Stoof</name></region><name sortKey="Booij, J" sort="Booij, J" uniqKey="Booij J" first="J" last="Booij">J. Booij</name><name sortKey="Drukarch, Benjamin" sort="Drukarch, Benjamin" uniqKey="Drukarch B" first="Benjamin" last="Drukarch">Benjamin Drukarch</name><name sortKey="Groenewegen, Henk J" sort="Groenewegen, Henk J" uniqKey="Groenewegen H" first="Henk J" last="Groenewegen">Henk J. Groenewegen</name><name sortKey="Stoof, Johannes C" sort="Stoof, Johannes C" uniqKey="Stoof J" first="Johannes C" last="Stoof">Johannes C. Stoof</name><name sortKey="Van Muiswinkel, Freek L" sort="Van Muiswinkel, Freek L" uniqKey="Van Muiswinkel F" first="Freek L" last="Van Muiswinkel">Freek L. Van Muiswinkel</name><name sortKey="Voorn, Pieter" sort="Voorn, Pieter" uniqKey="Voorn P" first="Pieter" last="Voorn">Pieter Voorn</name><name sortKey="Winogrodzka, Ania" sort="Winogrodzka, Ania" uniqKey="Winogrodzka A" first="Ania" last="Winogrodzka">Ania Winogrodzka</name><name sortKey="Wolters, Erik Ch" sort="Wolters, Erik Ch" uniqKey="Wolters E" first="Erik Ch" last="Wolters">Erik Ch Wolters</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4503C2812219952F69B54AD379C2EC391439570C
|texte= Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy
}}
| This area was generated with Dilib version V0.6.23. |  |